Maynard Um
-
-
-
-
-
-
-
MIRA Pharmaceuticals files Phase 2a trial protocol for CIPN drug
-
-
-
-
-
-
-
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
-
-
-
-
-
-
-
MIRA Pharmaceuticals starts final cohort of Ketamir-2 phase 1 trial
-
-
-
-
-
-
-
MIRA Pharmaceuticals completes SKNY acquisition, adds $5M in securities
-
-
-
-
-
-
-
MIRA Pharmaceuticals shareholders approve SKNY acquisition
-
-
-
-
-
-
-
MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
-
-
-
-
-
-
-
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisitio
-
426,816 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

